As central mediators of the DNA damage response, the BRCA1 and BRCA2 proteins normally act to preserve genome integrity. Indeed, their genome maintenance functions are thought to be a major, if not the principal, means by which BRCA1/2 suppress tumor formation in normal cells. In particular, BRCA1 and BRCA2 are required for double-strand DNA break repair by homologous recombination (DSBR-HR). However, recent studies have uncovered another BRCA1/2 function that also preserves genome stability and thus potentially contributes to the tumor suppression activity of both proteins. During DNA replication, BRCA1 and BRCA2 have been shown to promote genome integrity by protecting stalled replication forks (SRFs) from nucleolytic degradation. These findings raise critical questions regarding the mechanisms of BRCA1/2 tumor suppression and the prospects for therapeutic targeting of the BRCA1/2 pathway. For example, is the tumor suppression activity of the BRCA1/2 pathway mediated through its ability to promote DSBR-HR or SRF stability, or both? Also, can the DSBR-HR or SRF stability functions of BRCA1/2 be restored for prophylactic and/or therapeutic purposes in women who carry BRCA1/2 mutations? Our preliminary studies have uncovered a novel mechanism by which SRF stability can be reconstituted in BRCA1 mutant cells. In particular, we show that depletion of SMARCAL1, a DNA translocase implicated in replication fork dynamics, restores both SRF stability and chromosome integrity in BRCA1-deficient cells subjected to replication stress. On the basis of these results, we hypothesize that inappropriate remodeling of replication forks by SMARCAL1 in BRCA1- deficient cells can increase genome instability and thereby predispose these cells to breast cancer. To test these hypotheses, we will 1) define the mechanisms by which SMARCAL1 inactivation rescues SRF stability and chromosomal integrity in BRCA1-deficient cells, and 2) determine whether tumor suppression activity can be restored to BRCA1-mutant cells by SMARCAL1 inhibition.

Public Health Relevance

Inherited BRCA1 mutations predispose women to the more lethal forms of both breast (basal-like triple- negative) and ovarian (high-grade serous) cancer. Two aspects of BRCA1 function are proposed to be especially important for genome stability and, in turn, tumor suppression: DNA break repair by homologous recombination (DSBR-HR) and stalled replication fork (SRF) stability. This study will examine whether molecular interventions that restore SRF stability (e.g., by inhibition of the SMARCAL1 translocase) will suppress the tumorigenicity of BRCA1-mutant cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA227450-01A1
Application #
9670515
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Pelroy, Richard
Project Start
2019-01-01
Project End
2022-12-31
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032